Emergency Task Force (Toronto Police Service)

Canadian police are becoming more militarized, and that is damaging public trust

Retrieved on: 
Sunday, June 4, 2023
Poverty, Violence, War, Life, Diplomacy, Emergency Task Force (Toronto Police Service), Hypervigilance, Toronto, Research, Nightmare, Canadian Armed Forces, Military personnel, Insomnia, ETF, Police, Dehumanization, City, Trauma, Drug, Telescopic sight, Nightclub, HMS Choudri

Choudry’s death renewed public concern about police use of force and draws attention to the use of police tactical units to respond to incidents involving people in mental distress.

Key Points: 
  • Choudry’s death renewed public concern about police use of force and draws attention to the use of police tactical units to respond to incidents involving people in mental distress.
  • In October 2022, the Toronto Police Service released a podcast episode about its tactical unit, the Emergency Task Force (ETF).
  • Why are police, who are meant to ensure public safety, increasingly mirroring military units designed for warfare?
  • It undermines public trust in the police and damages the very communities the police aim to serve.

Vincent LeVien Joins Oaktree Solutions as Managing Director for Hospitality and Security

Retrieved on: 
Monday, May 8, 2023
Other Communications, Public Relations, Investor Relations, Consulting, Marketing, Thought Leadership, Communications, Professional Services, Business, Other Travel, Travel, White House, Roman Catholic Diocese of Brooklyn, Tablet (newspaper), NET, Government, Congress, Diocese, Growth, Emergency Task Force (Toronto Police Service), Oak Tree

Oaktree Solutions announced today that Vincent LeVien has joined the firm as managing director for hospitality and security.

Key Points: 
  • Oaktree Solutions announced today that Vincent LeVien has joined the firm as managing director for hospitality and security.
  • “I am honored to be joining the Oaktree team,” said LeVien.
  • “Vincent embodies Oaktree's core principles of joy, value, and understanding,” said Oaktree Founder and Chairman Frank Carone.
  • Previously, LeVien worked for New York State Comptroller Thomas DiNapoli as director of intergovernmental affairs.

Jameson Shapiro shooting trial: Why police trials perform a vital public service

Retrieved on: 
Thursday, May 4, 2023
Human, Supreme Court of the United States, Special Investigations, Emergency Task Force (Toronto Police Service), Policy, Ontario Provincial Police, Public policy, Medicine, ETF, Modernization of Investigative Techniques Act, Shapiro, Police, Child, OPP, Supreme court, Radio, Death, Injury, Private investigator, Auction, Kawartha Lakes

They are accused of shooting and killing an 18-month-old baby, Jameson Shapiro, and his father William Shapiro in November 2020 in the Kawartha Lakes area northeast of Toronto.

Key Points: 
  • They are accused of shooting and killing an 18-month-old baby, Jameson Shapiro, and his father William Shapiro in November 2020 in the Kawartha Lakes area northeast of Toronto.
  • Police officer trials are important for reasons other than simply holding an individual officer accountable for a particular act.
  • Police trials also spur public debate on how repressive state force is administered.

Shifting public policy

    • A prime example of trials changing public policy is the 1985 United States Supreme Court ruling in Tennessee v. Garner that effectively prohibited the practice of shooting fleeing suspects in the back.
    • Courts in Canada have stopped or clarified when police can use overly invasive investigative techniques such as telephone wiretaps.
    • But there have been few occasions for police use-of-force practice and policy to be openly interrogated so that jurors could decide the “reasonableness” of officer conduct.

Regis Korchinski-Paquet death

    • A case that could have gone to trial involved the falling death of 29-year-old Regis Korchinski-Paquet in Toronto in May 2020.
    • She soon fell to her death.
    • The Special Investigations Unit’s report into Korchinski-Paquet’s death states that the decision-making officer told investigators he believed the best option was to refer the matter to the Emergency Task Force.

Jameson Shapiro’s death

    • The Kawartha Lakes OPP officers will be tried for manslaughter and criminal negligence causing death.
    • What happened next will likely become clear at trial as officers opened fire, striking William and killing Jameson on the scene.
    • William was suspected of being armed — a gun was recovered at the scene — and officers were told Jameson was in the car’s back seat.

Not just about convictions

    • Increasing the number of criminal trials for police officers won’t necessarily result in convictions.
    • But convictions aren’t their only purpose.
    • While public trust in police is eroding across the country, most Canadians still trust police.

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Retrieved on: 
Tuesday, September 13, 2022
Hospital, Atea, Call, HCV, Rest, COVID-19, Risk, FDA, Food, Patient, Virology, Virus, European Medicines Agency, Severe acute respiratory syndrome coronavirus 2, Population, Company, Genta (company), Private Securities Litigation Reform Act, Emergency Task Force (Toronto Police Service), Dengue virus, Respiratory syncytial virus, Degenerative disease, Regulation of tobacco by the U.S. Food and Drug Administration, RSV, SOC, Event, Biology, Standard of care, Immunodeficiency, Investor relations, Annual report, Nasdaq, Founder, Biochemistry, Doctor of Philosophy, RNA, GLOBE, BID, SEC, HIV disease progression rates, EMA, Death, Pharmaceutical industry, Medical imaging, Vaccine, Conference

BOSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced additional details on its clinical development plans for bemnifosbuvir for the treatment of COVID-19. Following meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Emergency Task Force, Atea plans to initiate a global Phase 3 registrational clinical trial of bemnifosbuvir for the treatment of COVID-19 in the fourth quarter of 2022. The trial will evaluate bemnifosbuvir as both monotherapy and combination antiviral therapy in outpatients (non-hospitalized) with COVID-19 who are at the highest risk of disease progression, regardless of vaccination status.

Key Points: 
  • Results from the late-stage MORNINGSKY trial showed a 71% reduction in hospitalization (secondary endpoint) with bemnifosbuvir versus placebo (p=0.047, unadjusted, exploratory) (n=207).
  • This novel Phase 3 trial design puts us at the forefront of clinical research for new COVID-19 antiviral therapies.
  • The randomized, double-blind, placebo-controlled, global Phase 3 study will evaluate bemnifosbuvir or placebo administered concurrently with locally available standard of care (SOC).
  • The study is designed to enroll at least 1,500 high-risk non-hospitalized patients with mild or moderate COVID-19.

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 8, 2022
High-risk pregnancy, Public health, GLOBE, Death, NS5A, Clinical trial, Research, Patient, Hospital, Final Analysis, Viral load, Atea, Development, Food, Combination therapy, Income, Omicron, Merck, Fever Dream, DENV, Safety, Doctor of Philosophy, Nasdaq, Pharmacokinetics, Alpha, European Medicines Agency, Protease, COVID-19, Virology, Vaccine, Infection, Immunodeficiency, RZR, Delta, Cash, Food and Drug Administration, Severe acute respiratory syndrome coronavirus 2, HCV, EMA, Dengue fever, FDA, BID, Ritonavir, Founder, Emergency Task Force (Toronto Police Service), Therapy, Income tax, Dengue virus, Personal income in the United States, Administration, Adult, Pharmaceutical industry, Life insurance, Vitro

New antivirals with improved profiles are urgently needed, said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.

Key Points: 
  • New antivirals with improved profiles are urgently needed, said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • For dengue, we are currently enrolling two proof-of-concept trials for AT-752 and expect initial results in late 2022.
  • Operational planning for this trial is currently underway with the goal of initiation during the fourth quarter of 2022.
  • Results from the human challenge trial and initial results from the DEFEND-2 study are expected in the fourth quarter of 2022.

European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries

Retrieved on: 
Wednesday, July 27, 2022
Form 10-Q, Flash, CDK, Zuclomifene, European Medicines Agency, Safety, Review, Company, Security (finance), Infection, Emergency Task Force (Toronto Police Service), Death, Public sector, MHRA, U.S. Securities and Exchange Commission, EMA, Finasteride, COVID, Breast, AR, GLOBE, Capsule, Insurance, Female, Medicine, Telehealth, Government, Fast Track, COVID-19, Pregnancy, Eli Lilly and Company, FDA, ETF, Man, Vaccine, Tadalafil, Trial of the century, NEJM, Forward-looking statement, Acute respiratory distress syndrome, FC2, Prostate cancer, Private Securities Litigation Reform Act, Collection, Management of prostate cancer, Risk, The New England Journal of Medicine, NASDAQ, Lilly, CHMP, Gonadotropin-releasing hormone, Patient, Efficiency, WHO, Pharmaceutical industry, Birth control, Medical imaging, EU

The results of this study would indicate that sabizabulin treatment reduces the number of deaths in these patients compared with placebo (a dummy treatment).

Key Points: 
  • The results of this study would indicate that sabizabulin treatment reduces the number of deaths in these patients compared with placebo (a dummy treatment).
  • .The review will assist EU Member States who may consider allowing use of the medicine before a possible authorisation.
  • The ETF will conduct this review and send recommendations to the Agencys human medicines committee (CHMP), which will issue the Agencys opinion.
  • By reducing deaths in hospitalized COVID-19 patients, sabizabulin has great potential to play a critical role in the battle against COVID-19 in the EU.